In support of this hypothesis, previous studies showed that PRELP is localized in the nucleus as well as cytoplasm of hepatocellular carcinoma tissues (22), and the N-terminal peptide of PRELP is also translocated to the nucleus where it inhibits the DNA-binding activity of NF-κB (46). This evidence concerns the gene NFKB1 and hepatocellular carcinoma.